M Scott Maguire
Chief Executive Officer
M Scott Maguire joined Xenetic in April 2004 as Chief Executive Officer. He has more than 22 years of life sciences and healthcare investment banking executive experience and he has advised many U.S. and European companies on capital raisings, M&A and commercial development. Mr. Maguire began his banking career with Merrill Lynch based in New York. He later joined the healthcare division of W.R. Grace National Medical Care based in Waltham, MA, where he helped expand the international healthcare division and doubled international revenues through mergers and acquisitions. In 1996, he moved to Europe to co-found the Arthur Andersen global healthcare corporate finance practice based in London. Mr. Maguire is currently non-executive director of Healthcare Capital Partners Limited, a healthcare corporate finance and investment boutique he co-founded in 2002, and a non-executive director of Renal Services Ltd, a company focused on dialysis service provision in the UK. Mr. Maguire earned his M.B.A.
Jeffrey F. Eisenberg
Chief Operating Officer
Jeffrey F. Eisenberg joined the Xenetic Management team in December 2016 and has served on the Company’s Board of Directors since July 2016. He is a life sciences executive with over 20 years of operational experience and a successful track record in value creation in both private and public companies. Over the course of his career, he has led all crucial areas of R&D, operations, manufacturing/quality, business development, strategic partnering, product development, commercialization, and talent management. Prior to joining the Xenetic Board, Mr. Eisenberg served at Noven Pharmaceuticals, Inc. for over a decade beginning as Vice President, General Counsel and Corporate Secretary and departing as the President and CEO and a member of the Board of Directors. Mr. Eisenberg also served as Senior Vice President of Strategic Alliances, Interim President and CEO, and Executive Vice President while serving at Noven. Currently, Mr. Eisenberg serves as a member of the Board of Directors of Mabvax Therapeutics, Inc.
Curtis Lockshin, Ph.D.
Chief Scientific Officer
Curtis A. Lockshin, Ph.D. joined the Xenetic Management team in January 2017 and has served as the Vice President of Research and Operations of the Company since March 2014. From July 2015 to July 2016, Dr. Lockshin served as Chief Executive Officer and Director of SciVac Therapeutics Inc., and its subsidiary SciVac, Ltd., a commercial-stage biologics and vaccine company in Rehovot, Israel, where he had been serving as CEO and Director since September 2014. Subsequent to SciVac Therapeutics' merger with VBI Vaccines, Inc. in July 2016, Dr. Lockshin served as Chief Technical Officer of VBI Vaccines and its subsidiary SciVac Ltd. In addition, he has served as President and CEO of Guardum Pharmaceuticals, LLC, a private pharmaceutical company, and previously as Vice President of Corporate R&D Initiatives for OPKO Health, Inc., a multinational pharmaceutical and diagnostics company. Dr. Lockshin has served as a member of the Board of Directors at a number of companies including R Xi Pharmaceuticals, Corp., ChromaDex, Inc., and Sorrento Therapeutics, Inc., as well as the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation that supports basic research related to Alzheimer's disease and neurodegeneration via intramural, extramural and international grants.
Henry Hoppe IV, Ph.D.
VP of Drug Development
Henry Hoppe IV, Ph.D. joined Xenetic in April of 2012 as Vice President of Drug Development. He is a biotechnology process development executive with more than 20 years of experience in recombinant protein, monoclonal antibody and stem cell expression for clinical therapies. Dr. Hoppe has written and reviewed IND/NDA CMC sections for numerous recombinant protein and gene therapy programs, including those for Cerezyme®, Fabrazyme®, Myozyme® and Thyrogen®, four currently marketed products coming out of Genzyme Corporation. He has experience with all aspects of therapeutic development from the bench through Phase 2 clinical trials including managing Clinical Manufacturing Organizations (CMOs) in both the United States and Europe.
Between 1980 and 1984, He held positions at the Harvard Medical School and the University Hospital of Boston.
From 1984 to 2001, Dr. Hoppe worked for Genzyme Corporation focusing on therapies for rare genetic diseases. He was subsequently appointed Vice President of Therapeutic Development for ViaCell Inc. where he delivered stem cells to clinical trials and designed Phase 2 manufacturing processes. In 2004, Dr. Hoppe founded his own consultancy business, BioDevelopment Consulting, to provide expertise in advancing therapies from research into Phase 1 and Phase 2 clinical trials.
Dr. Hoppe has Inventor status on four US granted patents addressing oncology, anaemia and cystic fibrosis diseases. He has authored numerous articles in noted scientific journals and has been the keynote speaker at a number of leading industry conferences. Dr. Hoppe holds a Ph.D. in Genetic Toxicology from Massachusetts Institute of Technology.